Global pharmaceutical leader Lupin (Lupin) has signed a license and supply agreement with Huons Co. to register and market Cyclosporine Ophthalmic Nanoemulsion, 0.4mL Single-use Vial, in Mexico.
The company in a press statement on Thursday informed that this preservative-free nanoemulsion, already approved in South Korea, Peru, and several Middle Eastern countries, is designed to treat dry eye syndrome and heal corneal ulcers.
Cyclosporine Ophthalmic Nanoemulsion employs unique nanoparticle technology to increase tear production in patients with keratoconjunctivitis sicca-related ocular inflammatory disease, offering faster symptom relief for those with suppressed tear formation.
“We are delighted to partner with Huons to introduce Cyclosporine Ophthalmic Nanoemulsion in Mexico and offer a novel technology that provides significant benefits to our patients suffering from dry eye,” said Fabrice Egros, President – Corporate Development and Growth Markets, Lupin. “With this addition to our Ophthalmology portfolio, we continue to strengthen our commitment to providing better healthcare and eye care solutions, improving patient quality of life and vision.”
Yohun Aum, Senior Director – Head of Global Business Division, Huons, added, “Introducing our Cyclosporine Ophthalmic Nanoemulsion in Mexico is a significant milestone for Huons. We look forward to strengthening our partnership by supplying high-quality products for Mexico.”
